Redcare Pharmacy Targets Growth and Margin Improvement in 2025

Following a strong 2024, Redcare Pharmacy anticipates significant growth in 2025, forecasting a 25% sales increase and a positive EBITDA margin of 2% to 2.5%. In 2024, the company reported a 32% rise in sales to EUR 2.37 billion and a 1.4% EBITDA margin. The DeutscheRx segment saw customer numbers doubling and sales growing by 64% to EUR 750 million. Record gains in customers pushed the overall base to 12.5 million.

Redcare also established itself as the market leader in Italy, adding to its leadership in other countries. Despite a 23.9% rise in gross profit to EUR 546 million, net results showed a loss of EUR 46.4 million. For 2025, a focus on Rx sales, expected to exceed EUR 0.5 billion in Germany, aims to drive further growth.